{"id":"W1242366555","doi":"10.1007/s00415-015-7834-0","title":"Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis","year":2015,"lang":"en","type":"article","venue":"Journal of Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"ca_institutions":"St. Michael's Hospital; Montreal Neurological Institute and Hospital","funders":"Novartis Pharma; National Research Foundation; Actelion Pharmaceuticals; Novartis; Teva Pharmaceutical Industries; Serono Symposia International Foundation","keywords":"Fingolimod; Medicine; Expanded Disability Status Scale; Multiple sclerosis; Discontinuation; Adverse effect; Placebo; Internal medicine; Randomized controlled trial; Neurology; Natalizumab; Clinical trial; Pathology; Psychiatry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005867427,0.001701138,0.003161959,0.0005721396,0.000967037,0.001466609,0.001218714,0.002236833,0.002374897],"category_scores_gemma":[0.003030581,0.0007725864,0.002694451,0.0005891622,0.001563894,0.002076688,0.0006771413,0.004618821,0.0008743569],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001026707,"about_ca_system_score_gemma":0.00181017,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002132085,"about_ca_topic_score_gemma":0.003174588,"domain_scores_codex":[0.9981008,0.0008637441,0.0001159843,0.0002541957,0.0002043254,0.0004610111],"domain_scores_gemma":[0.9966564,0.0007520104,0.0006613742,0.0004441412,0.00033382,0.001152139],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8911952,0.03600446,0.0120466,0.0003164253,0.002383833,0.0002513212,0.0003727868,0.001163484,0.02070618,0.0001096745,0.001665203,0.03378486],"study_design_scores_gemma":[0.4841811,0.41821,0.0876858,0.00005264955,0.002773082,0.0003670463,0.000200536,0.0007117526,0.00354545,0.000284762,0.001902367,0.00008554086],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958757,0.001630869,0.0002529794,0.0002477537,0.00007640165,0.0004053069,0.0009049904,0.00004067265,0.0005653857],"genre_scores_gemma":[0.9926021,0.0008409193,0.0007420686,0.0006714346,0.0001923645,0.0006207455,0.002889399,0.00002959141,0.001411445],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005867427,"threshold_uncertainty_score":0.03103024,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1744770482669709,"score_gpt":0.3546205121302032,"score_spread":0.1801434638632323,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}